JP2021502097A5 - - Google Patents

Download PDF

Info

Publication number
JP2021502097A5
JP2021502097A5 JP2020525971A JP2020525971A JP2021502097A5 JP 2021502097 A5 JP2021502097 A5 JP 2021502097A5 JP 2020525971 A JP2020525971 A JP 2020525971A JP 2020525971 A JP2020525971 A JP 2020525971A JP 2021502097 A5 JP2021502097 A5 JP 2021502097A5
Authority
JP
Japan
Prior art keywords
nucleotides
sgrna
sequence
composition
shortened
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020525971A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021502097A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/060126 external-priority patent/WO2019094791A2/en
Publication of JP2021502097A publication Critical patent/JP2021502097A/ja
Publication of JP2021502097A5 publication Critical patent/JP2021502097A5/ja
Priority to JP2023223638A priority Critical patent/JP2024019727A/ja
Withdrawn legal-status Critical Current

Links

Images

JP2020525971A 2017-11-10 2018-11-09 標的化ｃｒｉｓｐｒ送達プラットフォーム Withdrawn JP2021502097A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023223638A JP2024019727A (ja) 2017-11-10 2023-12-28 標的化ｃｒｉｓｐｒ送達プラットフォーム

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762584310P 2017-11-10 2017-11-10
US62/584,310 2017-11-10
US201762596375P 2017-12-08 2017-12-08
US62/596,375 2017-12-08
US201862667084P 2018-05-04 2018-05-04
US62/667,084 2018-05-04
PCT/US2018/060126 WO2019094791A2 (en) 2017-11-10 2018-11-09 Targeted crispr delivery platforms

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023223638A Division JP2024019727A (ja) 2017-11-10 2023-12-28 標的化ｃｒｉｓｐｒ送達プラットフォーム

Publications (2)

Publication Number Publication Date
JP2021502097A JP2021502097A (ja) 2021-01-28
JP2021502097A5 true JP2021502097A5 (https=) 2021-12-02

Family

ID=66438139

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020525971A Withdrawn JP2021502097A (ja) 2017-11-10 2018-11-09 標的化ｃｒｉｓｐｒ送達プラットフォーム
JP2023223638A Pending JP2024019727A (ja) 2017-11-10 2023-12-28 標的化ｃｒｉｓｐｒ送達プラットフォーム

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023223638A Pending JP2024019727A (ja) 2017-11-10 2023-12-28 標的化ｃｒｉｓｐｒ送達プラットフォーム

Country Status (13)

Country Link
US (3) US20220389447A9 (https=)
EP (1) EP3707254A4 (https=)
JP (2) JP2021502097A (https=)
KR (2) KR102922730B1 (https=)
CN (1) CN111868240A (https=)
AU (2) AU2018364993B2 (https=)
BR (1) BR112020009268A2 (https=)
CA (1) CA3082370A1 (https=)
CO (1) CO2020007046A2 (https=)
IL (2) IL317505A (https=)
MX (1) MX2020004777A (https=)
SG (1) SG11202005103RA (https=)
WO (1) WO2019094791A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3868887A4 (en) * 2018-09-25 2022-12-07 Microbial Chemistry Research Foundation NOVEL VIRAL VECTOR AND METHODS OF PRODUCTION AND USE THEREOF
CN113661392B (zh) 2019-02-05 2025-05-27 卡蒂亚生物公司 有效靶向基因组操纵剂的增强选择
US20220298494A1 (en) * 2019-02-14 2022-09-22 Metagenomi Ip Technologies, Llc Enzymes with ruvc domains
CN110257406B (zh) * 2019-06-21 2022-07-22 安徽省农业科学院水稻研究所 密码子植物化改造的Plant Nme2Cas9基因及其应用
US12297426B2 (en) 2019-10-01 2025-05-13 The Broad Institute, Inc. DNA damage response signature guided rational design of CRISPR-based systems and therapies
WO2021122944A1 (en) 2019-12-18 2021-06-24 Alia Therapeutics Srl Compositions and methods for treating retinitis pigmentosa
CN113652411B (zh) * 2021-07-30 2025-01-10 复旦大学 Cas9蛋白、含有Cas9蛋白的基因编辑系统及应用
CA3225082A1 (en) 2021-08-27 2023-03-02 Brian C. Thomas Enzymes with ruvc domains
US20230183687A1 (en) * 2021-10-13 2023-06-15 University Of Massachusetts Modified guide rnas for neisseria meningitidis cas9
WO2023081687A1 (en) * 2021-11-03 2023-05-11 Intellia Therapeutics, Inc. Modified guide rnas for gene editing
EP4426822A2 (en) 2021-11-03 2024-09-11 Intellia Therapeutics, Inc. Polynucleotides, compositions, and methods for genome editing
WO2023240076A1 (en) 2022-06-07 2023-12-14 Scribe Therapeutics Inc. Compositions and methods for the targeting of pcsk9
WO2024137766A2 (en) 2022-12-21 2024-06-27 Intellia Therapeutics, Inc. Compositions and methods for proprotein convertase subtilisin kexin 9 (pcsk9) editing
WO2024186890A1 (en) 2023-03-06 2024-09-12 Intellia Therapeutics, Inc. Compositions and methods for hepatitis b virus (hbv) genome editing
TW202515994A (zh) 2023-08-14 2025-04-16 美商英特利亞醫療公司 用於對ｃｄ７０進行基因修飾之組合物及方法
WO2025038637A1 (en) 2023-08-14 2025-02-20 Intellia Therapeutics, Inc. Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2)
TW202521564A (zh) 2023-08-14 2025-06-01 美商英特利亞醫療公司 用於基於細胞之療法的ｃｄ７０ ｃａｒ－ｔ組合物及方法
AU2024324870A1 (en) 2023-08-14 2026-02-12 Intellia Therapeutics, Inc. Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2)
WO2025255308A1 (en) 2024-06-07 2025-12-11 Intellia Therapeutics, Inc. Cd8 co-receptor chimeric polypeptides in tcr cell therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3241902B1 (en) * 2012-05-25 2018-02-28 The Regents of The University of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
MX2015017312A (es) * 2013-06-17 2017-04-10 Broad Inst Inc Suministro y uso de composiciones, vectores y sistemas crispr-cas para la modificación dirigida y terapia hepáticas.
WO2015006294A2 (en) * 2013-07-10 2015-01-15 President And Fellows Of Harvard College Orthogonal cas9 proteins for rna-guided gene regulation and editing
EP3760719A1 (en) * 2013-11-18 2021-01-06 CRISPR Therapeutics AG Crispr-cas system materials and methods
CN106103699B (zh) * 2013-11-28 2019-11-26 地平线探索有限公司 体细胞单倍体人类细胞系
JP6793547B2 (ja) * 2013-12-12 2020-12-02 ザ・ブロード・インスティテュート・インコーポレイテッド 最適化機能ＣＲＩＳＰＲ−Ｃａｓ系による配列操作のための系、方法および組成物
EP3080259B1 (en) 2013-12-12 2023-02-01 The Broad Institute, Inc. Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
WO2016049258A2 (en) * 2014-09-25 2016-03-31 The Broad Institute Inc. Functional screening with optimized functional crispr-cas systems
US10190106B2 (en) * 2014-12-22 2019-01-29 Univesity Of Massachusetts Cas9-DNA targeting unit chimeras
US20160346359A1 (en) * 2015-05-01 2016-12-01 Spark Therapeutics, Inc. Adeno-associated Virus-Mediated CRISPR-Cas9 Treatment of Ocular Disease
WO2018085414A1 (en) * 2016-11-02 2018-05-11 President And Fellows Of Harvard College Engineered guide rna sequences for in situ detection and sequencing
BR112019028146A2 (pt) * 2017-07-31 2020-07-07 Sigma-Aldrich Co. Llc rna guia sintético para sistemas ativadores de crispr/cas

Similar Documents

Publication Publication Date Title
JP2021502097A5 (https=)
AU2023200084B2 (en) Targeted CRISPR delivery platforms
Guo et al. Harnessing accurate non-homologous end joining for efficient precise deletion in CRISPR/Cas9-mediated genome editing
KR102699944B1 (ko) Rna-가이드된 엔도뉴클레아제를 이용하는 게놈 조작에서 특이성을 개선하는 조성물 및 방법
JP2024121000A (ja) Ｎｍｅ２Ｃａｓ９－デアミナーゼ融合タンパク質によるブログラム可能なＤＮＡ塩基編集
CN108779466B (zh) 用于通过基因编辑修正人肌营养不良蛋白基因的治疗靶标和使用方法
CN109890424A (zh) 用于治疗视网膜变性的基于crispr/cas9的组合物和方法
KR102621539B1 (ko) 인위적으로 조작된 sc 기능 조절 시스템
EP3353296A1 (en) Use of exonucleases to improve crispr/cas-mediated genome editing
Pankowicz et al. CRISPR/Cas9: at the cutting edge of hepatology
US20240175056A1 (en) Prime editing-based simultaneous genomic deletion and insertion
KR102847166B1 (ko) 항응고 인자들의 유전자 에디팅
US20210092942A1 (en) Novel immunodeficient rat for modeling human cancer
Ichida et al. Differential regulation of exonic regulatory elements for muscle-specific alternative splicing during myogenesis and cardiogenesis
KR20240038705A (ko) 간 유전자의 생체 내 편집 방법
Kazazian et al. " Copy and paste" transposable elements in the human genome.
CA3190360C (en) Modified cas9 system having a dominant negative effector on non-homologous end-joining fused thereto and its use for improved gene editing
CN115747257B (zh) 一种使用转基因小鼠对基因编辑技术进行安全性评价的方法
Kornberg Correction: Targeted gene correction in the mdx mouse using short DNA fragments: towards application with bone marrow-derived cells for autologous remodeling of dystrophic muscle
US20230227818A1 (en) Clinically applicable characterization of genetic variants by genome editing
Ibraheim et al. Let us know how access to this document benefits you.
Price CRISPR/Cas9-mediated gene editing in the arginase-1 deficient mouse genome
EA046214B1 (ru) Композиции и способы улучшения специфичности в геномной инженерии с применением рнк-направляемых эндонуклеаз